Stemline Therapeutics (STML) a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercialization of proprietary oncology therapeutics.
STML develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which is in Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm, myeloproliferative neoplasms, and acute myeloid leukemia; and in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma. It also develops SL-801, a novel oral small molecule reversible inhibitor of a tumor-promoting nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that is in Phase II clinical trial to attack brain cancer.
STML also develops SL-501, a next generation IL-3R-targeted therapy that is in preclinical development.
Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.
May 16, 2020 - 12:13pm |
Out and About, Research Notes, Out and About, Earnings Q1
Athersys (ATHX), Homology Medicine (FIXX), Verastem (VSTM), EDITAS Medicine (EDIT), REGENXBIO (RGNX), Caladius Biosciences (CLBS), Bellicum Pharmaceuticals (BLCM),, uniQure (QURE), CRISPR Therapeutics (CRSP),Aduro Biotech (ADRO), Brainstorm Cell Therapeutics (BCLI), Editas medicine (EDIT), Global Blood Therapeutics (GBT), Inyellia Therapeutics (NTLA), Ionis Pharmaceuticals (IONS), Ultragenyx (RARE), Voyager Therapeutics (VYGR), Solid Biosciences (SLDB), MiMedx (MDXG), Stemline Therapeutics (STML) acquired by Menarini, an Italian pharma, Fate therapeutics (FATE), Sangamo Therapeutics (SGMO), bluebird bio (BLUE), BioLife Solutions BLFS, Biostage (BSTG), Pluristem (PSTI)
- April 11, 2020 - 1:23pm | Out and About, Research Notes, Out and About, Earnings, Earnings Q4
- November 3, 2019 - 2:45pm | Out and About, Research Notes, Out and About, Earnings
- August 8, 2019 - 10:30am | Out and About, Out and About, Financings
- January 29, 2019 - 12:50pm | Out and About, Out and About
- January 16, 2019 - 3:44am | Out and About, Research Notes, Out and About, Financings
- November 9, 2018 - 8:39am | Out and About, Research Notes, Out and About, Earnings
- September 11, 2018 - 1:18pm | Out and About, Research Notes, Out and About, Earnings, Earnings Q2
- June 2, 2018 - 7:11am | Out and About, Out and About, Earnings, Earnings Q1
- March 10, 2018 - 9:22am | Earnings, Earnings Q4
- March 4, 2018 - 11:11am | Analysis, Out and About
- January 22, 2018 - 5:00pm | Out and About, Financings
- November 3, 2017 - 1:08pm | Earnings, Earnings Q3
- May 5, 2017 - 8:59am | Earnings, Earnings Q1
- March 10, 2017 - 12:00am | Earnings, Earnings Q4
- February 7, 2017 - 12:42pm | Research Notes
- January 19, 2017 - 4:54pm | Research Notes, Financings
- November 2, 2016 - 8:46pm | Earnings, Earnings Q3
- August 23, 2016 - 8:42am | Research Notes
- August 4, 2016 - 10:50pm | Earnings, Earnings Q2